Conducting more clinical trials in developing countries is of benefit because these populations are underrepresented in research, but doing trials in resource poor settings has many challenges. Research sites in developing countries benefit from working with externally sponsored clinical trials including increased capacity development and investment, but locally led research is also challenged by complex trial regulations and administrative burdens.

In a study of more than 1,000 adults, researchers at the University of California, San Diego, found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both.

In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.

A study led by Karolinska Institutet reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a cure for this seriously debilitating dementia disease. The study is published in the distinguished scientific journal Lancet Neurology.

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

Results from a study published online in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in complete or near complete remission in a majority of patients with newly diagnosed multiple myeloma.

Researchers at the University of Toronto Scarborough (UTSC) used an innovative technique to examine chemical interactions that are implicated in Parkinson's Disease. The work details how a protein called alpha-synuclein interacting with the brain chemical dopamine can lead to protein misfolding and neuronal death.